Jennifer C Spencer1, Noel T Brewer1, Justin G Trogdon1, Stephanie B Wheeler1, Stacie B Dusetzina1. 1. At the time of the study, Jennifer C. Spencer, Stephanie B. Wheeler, Justin G. Trogdon, and Stacie B. Dusetzina were with the Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Noel T. Brewer was with the Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill. Stacie B. Dusetzina was also with the Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill.
Abstract
OBJECTIVES: To assess predictors of timely human papillomavirus (HPV) vaccine follow-through among privately insured individuals initiating the 3-dose series. METHODS: Using MarketScan Commercial claims data, we identified 1 332 217 privately insured US individuals aged 9 to 26 years who initiated the bivalent or quadrivalent HPV vaccine series from 2006 to 2014, with follow-up data extending through 2015. The study outcome was receipt of third HPV dose within 12 months of the first, compared by year of initiation. Control variables were age, region, insurance plan type, provider type, and seasonal influenza vaccination. RESULTS: Timely HPV vaccine follow-through fell over time. The trend was especially pronounced for females (from 67% in 2006 to 38% in 2014), but was also present for males (from 36% in 2011 to 33% in 2014). Similar patterns were present when we controlled for patient and provider characteristics or used alternative definitions of follow-through. Other positive predictors of timely follow-through included receipt of flu vaccine in the prior year and receipt of first HPV vaccine dose from an obstetrician/gynecologist. CONCLUSIONS: HPV vaccine follow-through is low and has declined over time.
OBJECTIVES: To assess predictors of timely human papillomavirus (HPV) vaccine follow-through among privately insured individuals initiating the 3-dose series. METHODS: Using MarketScan Commercial claims data, we identified 1 332 217 privately insured US individuals aged 9 to 26 years who initiated the bivalent or quadrivalent HPV vaccine series from 2006 to 2014, with follow-up data extending through 2015. The study outcome was receipt of third HPV dose within 12 months of the first, compared by year of initiation. Control variables were age, region, insurance plan type, provider type, and seasonal influenza vaccination. RESULTS: Timely HPV vaccine follow-through fell over time. The trend was especially pronounced for females (from 67% in 2006 to 38% in 2014), but was also present for males (from 36% in 2011 to 33% in 2014). Similar patterns were present when we controlled for patient and provider characteristics or used alternative definitions of follow-through. Other positive predictors of timely follow-through included receipt of flu vaccine in the prior year and receipt of first HPV vaccine dose from an obstetrician/gynecologist. CONCLUSIONS:HPV vaccine follow-through is low and has declined over time.
Authors: Paul L Reiter; Kunal Gupta; Noel T Brewer; Melissa B Gilkey; Mira L Katz; Electra D Paskett; Jennifer S Smith Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-03-14 Impact factor: 4.254
Authors: Parth D Shah; William A Calo; Melissa B Gilkey; Marcella H Boynton; Susan Alton Dailey; Karen G Todd; Meagan O Robichaud; Marjorie A Margolis; Noel T Brewer Journal: Pediatrics Date: 2019-01-22 Impact factor: 7.124
Authors: Mary A Gerend; Yesenia P Stephens; Michelle M Kazmer; Elizabeth H Slate; Elena Reyes Journal: J Adolesc Health Date: 2019-02-15 Impact factor: 5.012
Authors: Abbey B Berenson; Jacqueline M Hirth; Erika L Fuchs; Mihyun Chang; Richard E Rupp Journal: Hum Vaccin Immunother Date: 2019-12-06 Impact factor: 3.452
Authors: Lane McLendon; Jesse Puckett; Chelsea Green; Jenna James; Katharine J Head; Hee Yun Lee; Jennifer Young Pierce; Mark Beasley; Casey L Daniel Journal: Hum Vaccin Immunother Date: 2020-12-16 Impact factor: 3.452
Authors: Summer Sherburne Hawkins; Krisztina Horvath; Jessica Cohen; Lydia E Pace; Christopher F Baum Journal: BMC Public Health Date: 2021-02-06 Impact factor: 3.295